Japan· JP-2655708N1318
ビホナゾール
A bifonazole product containing ビホナゾール, registered in Japan by 岩城製薬, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Bifonazole is registered in 10 of 19 countries.
Countries holding a registration under ATC D01AC10 (bifonazole), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Bifonazole · ATC D01AC10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ビホナゾール
- Manufacturer
- 岩城製薬
- Country
- Japan (JP)
- ATC code
- D01AC10
- ATC class
- Bifonazole
- Defined daily dose
- 10 mg, T
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under D01AC10
Bifonazole, as other registers publish it.
- FranceAMYCOR 1 POUR CENT, crème pour application localeMERCK SANTE
- FranceAMYCOR 1 POUR CENT, poudre pour application locale en flacon poudreurMERCK SANTE
- GermanyBifonDermapharm Ag
- GermanyBifonazol AristoAristo Pharma Gmbh (Art 57)
- FranceBIFONAZOLE SUBSTIPHARM 1 %, crèmeSUBSTIPHARM
- PolandCanesporBayer Sp. z o.o.
- PolandCanesporInPharm Sp. z o.o.
- FinlandCanesporBayer Oy
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e13b178c-2e98-4fda-afab-5a3416533d4d GET /v1/drugs/e13b178c-2e98-4fda-afab-5a3416533d4d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１％１ｇ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2655708N1318",
"category": "外用薬",
"price_yen": 10.9,
"generic_name": "ビホナゾール",
"product_name_jp": null,
"therapeutic_class": "2655",
"transitional_expiry": null
}See everything about bifonazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.